HC Wainwright & Co. Reiterates Buy on Annovis Bio, Maintains $30 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. has reiterated its Buy rating on Annovis Bio (NYSE:ANVS) and maintained a price target of $30.
August 15, 2024 | 11:39 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
HC Wainwright & Co. has reiterated its Buy rating on Annovis Bio and maintained a price target of $30.
The reiteration of a Buy rating and maintenance of a $30 price target by a reputable analyst can positively influence investor sentiment and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100